Literature DB >> 12465701

Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer.

Andrew Davies1, Susan Brailsford, Karen Broadley, David Beighton.   

Abstract

The aim of this study was to determine the prevalence of in vitro resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. The National Committee for Clinical Laboratory Standards' broth microdilution method was used to determine the sensitivities to fluconazole, itraconazole, ketoconazole, and nystatin, whilst the Etest method was used to determine the sensitivity to amphotericin B. The prevalence of in vitro resistance was: amphotericin B, 2%; fluconazole, 8%; itraconazole, 22%; ketoconazole, 7%; nystatin, 0%. Moreover, 28% of the yeasts was resistant to one or more of the azole group of anti-fungal drugs. The results of this study suggest that azole resistance may become a clinical problem in palliative care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465701     DOI: 10.1191/0269216302pm583oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  4 in total

Review 1.  MASCC/ISOO expert opinion on the management of oral problems in patients with advanced cancer.

Authors:  Jac A Jones; Yanin Chavarri-Guerra; Luisa Barreto Costa Corrêa; David R Dean; Joel B Epstein; Eduardo R Fregnani; Jiyeon Lee; Yuhei Matsuda; Valeria Mercadante; Ragnhild Elisabeth Monsen; Natasja J H Rajimakers; Deborah Saunders; Enrique Soto-Perez-de-Celis; Mariana S Sousa; Arghavan Tonkaboni; Arjan Vissink; Keng Soon Yeoh; Andrew N Davies
Journal:  Support Care Cancer       Date:  2022-06-18       Impact factor: 3.603

2.  Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.

Authors:  Joel B Epstein; Edmond L Truelove; Kimberly Hanson-Huggins; Lloyd A Mancl; Alice Chen; Oliver W Press; Stephen H Petersdorf; Thomas R Fritsche; Joshua D Epstein
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

3.  Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis.

Authors:  You Bum Song; Moo Kyu Suh; Gyoung Yim Ha; Heesoo Kim
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

4.  Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans.

Authors:  Madhushree M Routh; Nitin M Chauhan; S Mohan Karuppayil
Journal:  Braz J Microbiol       Date:  2014-01-15       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.